

Building a Strategic Focus on Data... Transitioning to a New Paradigm

Allison Brailey, Biogen, Cambridge, MA, USA

Joanna Koft, Biogen, Cambridge, MA, USA

Lynn Difinizio, Biogen, Cambridge, MA, USA

As the landscape shifts towards complex analyses, growing trends in outsourcing and expanding regulations for data sharing, building out traditional Biometrics roles to strengthen the analytical and strategic aspects of the end-to-end data flow is an important step in the progression of the drug development industry. Our new Clinical Data Sciences department facilitates this development with the establishment of four core functions: Data Planning, Data Operations, Quality and Process Management and Data and Analysis Infrastructure. Through the new focus on data reuse and sharing as well as data strategy, the Data Planning function brings an advantageous element to CDS. Developing a Data Strategy upfront, and maintaining it throughout the lifecycle of a drug program enables a more effective data flow for data sharing and re-use downstream, and serves as a tool to assist a data scientist in well-informed, risk-based decision making.

CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the author at:

Joanna Koft
Biogen, Inc.
300 Binney Street
Cambridge, MA 02142
Work Phone: 1.617.679.2980
Email: joanna.koft@biogen.com
Web: www.biogen.com

Brand and product names are trademarks of their respective companies.